Saskatoon, SK., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning developer of drone solutions, software, and robotics, today announced the closing of its previously announced registered direct offering of 7,150,000 common shares (or pre-funded warrants in lieu thereof) of the Company at a price of US$7.00, for gross proceeds of approximately US$50.0 million, before deducting placement agent discounts and offering expense ...

Core Viewpoint - Draganfly Inc. has announced a registered direct offering of 7,150,000 common shares at a price of US$7.00, aiming for gross proceeds of approximately US$50.0 million before expenses [1]. Group 1: Offering Details - The offering is being led by Maxim Group LLC, with Raymond James Ltd. and Ladenburg Thalmann & Co. Inc. as co-placement agents [2]. - The expected closing date for the offering is around February 27, 2026, pending customary closing conditions [3]. - The offering is subject to regulatory approvals from the Canadian Securities Exchange and notification to the Nasdaq Stock Market [4]. Group 2: Use of Proceeds - Draganfly intends to utilize the net proceeds for general corporate purposes, including funding new product capabilities, growth initiatives, working capital, and ongoing development and marketing of core products [3]. Group 3: Regulatory Compliance - The offering is made under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission and the Company's Canadian short form base shelf prospectus [5]. - A prospectus supplement will be filed with relevant securities commissions in Canada and the SEC in the U.S. [6]. Group 4: Company Overview - Draganfly Inc. is a pioneer in drone solutions, AI-driven software, and robotics, with over 25 years of innovation in various sectors including public safety, agriculture, and industrial inspections [8].

HONG KONG, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Abits Group Inc (NASDAQ: ABTS) (the “Company”), a new generation digital center with inhouse bitcoin mining operations, today announced that it has entered into definitive agreements in a registered direct offering with institutional investors for the purchase and sale of approximately $2.1 million of Ordinary Shares and pre-funded warrants at a price of $2.65 per Ordinary Share. The entire transaction has been priced at the market under Nasdaq rules. The offerin ...

Core Viewpoint - Bitdeer Technologies Group has announced a registered direct offering of 5,503,030 Class A ordinary shares at a price of US$7.94 per share, aiming to raise approximately US$43.5 million in net proceeds, which will be used for various corporate purposes including debt repayment and business expansion [1][2][3]. Group 1: Offering Details - The registered direct offering is priced at US$7.94 per Class A ordinary share and is expected to close on February 26, 2026, subject to customary closing conditions [1]. - The net proceeds from the registered direct offering are estimated to be around US$43.5 million after deducting offering expenses [2]. - The offering is part of a broader financing strategy that includes a separate private offering of 5.00% Convertible Senior Notes due 2032, which could raise approximately US$315.1 million [2]. Group 2: Use of Proceeds - Bitdeer plans to allocate approximately US$29.2 million of the proceeds to cover the costs of capped call transactions [3]. - An estimated US$138.2 million will be used to repurchase US$135.0 million of its 5.25% convertible senior notes due 2029 [3]. - Remaining proceeds will be directed towards datacenter expansion, high-performance computing (HPC) and AI cloud business expansion, ASIC-based mining rig development, and general corporate purposes [3]. Group 3: Transaction Contingencies - The completion of the registered direct offering is contingent upon the successful completion of the notes offering and the note repurchase transactions [4]. - The notes offering is not contingent on the completion of the registered direct offering or the note repurchase transactions [4]. Group 4: Company Overview - Bitdeer Technologies Group is a leading technology company specializing in Bitcoin mining and AI infrastructure, providing comprehensive solutions including equipment procurement, datacenter design, and operations [7][8]. - The company is headquartered in Singapore and has deployed datacenters in various countries including the United States, Norway, and Bhutan [8].

Group 1 - Altimmune, Inc. has closed a registered direct offering of 17,045,454 shares, generating approximately $75 million in gross proceeds before fees and expenses [1][2] - The funds will be used for the upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH) and for general corporate purposes [2] - The offering was facilitated by Titan Partners, acting as the sole placement agent [3] Group 2 - Pemvidutide, Altimmune's lead candidate, is a dual-action therapy targeting glucagon and GLP-1 receptors, showing potential as a differentiated treatment for MASH [2][6] - The company has received Breakthrough Therapy Designation from the U.S. FDA for pemvidutide, indicating its significance in addressing serious liver diseases [2] - Altimmune is focused on delivering long-term value for shareholders while enhancing its operational flexibility through this investment [2]

Core Viewpoint - Solid Power, Inc. has entered into a securities purchase agreement with a sector-focused institutional investor for the sale of common stock and warrants, indicating a strategic move to raise capital for its solid-state battery technology development [1] Group 1: Securities Purchase Agreement - The agreement involves the purchase and sale of 17,000,000 shares of common stock [1] - It includes pre-funded warrants to purchase an aggregate of 5,807,018 shares of common stock [1] - Additionally, the agreement features common warrants to purchase up to an aggregate of 45,614,036 shares of common stock [1]

Core Viewpoint - Altimmune, Inc. has entered into a securities purchase agreement for the sale of 17,045,454 shares of common stock, expected to generate approximately $75 million in gross proceeds, to fund its Phase 3 trial for pemvidutide and for general corporate purposes [1][2]. Group 1: Offering Details - The offering involves 17,045,454 shares of common stock or pre-funded warrants, with gross proceeds anticipated to be around $75 million before expenses [1]. - The offering is expected to close on or about January 29, 2026, pending customary closing conditions [1]. - Titan Partners is acting as the sole placement agent for this offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to prepare for the upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH), along with working capital and general corporate purposes [2]. - Pemvidutide is a dual agonist targeting glucagon and GLP-1 receptors, showing potential as a differentiated therapy for MASH, supported by recent Phase 2b data and Breakthrough Therapy Designation from the U.S. FDA [2]. Group 3: Company Overview - Altimmune is a late clinical-stage biopharmaceutical company focused on therapies for serious liver diseases, with pemvidutide as its lead candidate [6]. - The company aims to deliver significant patient impact and long-term shareholder value through its innovative therapies [2].

Group 1 - Arbe Robotics (ARBE) has priced an underwritten offering of 11,500,000 ordinary shares at a purchase price of $1.40 per share, estimating gross proceeds of approximately $16.1 million before deducting underwriting discounts and commissions and other offering expenses [1] - The company expects to grant underwriters a 30-day option to purchase up to an additional 1,725,000 ordinary shares at the public offering price, less underwriting discounts and commissions [1] - The offering is anticipated to close on or about January 27, subject to customary closing conditions, with net proceeds intended for working capital and general corporate purposes [1] Group 2 - Canaccord Genuity is acting as the sole bookrunner for the offering, while Roth Capital Partners and WestPark Capital are serving as co-managers [1]

Company Overview - China SXT Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (TCMPs) and TCM Homologous Supplements (TCMHS) [7] - The company was founded in 2005 and is headquartered in Taizhou City, Jiangsu Province, China [7] Offering Details - Univest Securities, LLC announced the closing of a registered direct offering of approximately $10 million for China SXT Pharmaceuticals [1] - The offering involved the sale of 66,666,666 Class A ordinary shares at a purchase price of $0.15 per share [2] - The gross proceeds from the offering were approximately $10 million, with Univest acting as the sole placement agent [3] Regulatory Compliance - The registered direct offering was made under a shelf registration statement on Form F-3, which became effective on December 1, 2025 [4]

Group 1 - China SXT Pharmaceuticals Inc. has entered into a definitive agreement for the purchase and sale of 66,666,666 Class A ordinary shares at a price of $0.15 per share in a registered direct offering [1] - The aggregate gross proceeds from this offering are expected to be approximately $10 million, with the transaction expected to close on or about January 12, 2026 [2] - The offering is being made pursuant to a shelf registration statement on Form F-3 that became effective on December 1, 2025, and a final prospectus supplement will be filed with the SEC [3] Group 2 - China SXT Pharmaceuticals Inc. is an innovative pharmaceutical company founded in 2005, focusing on the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces [5]